Immunogenicity and Safety of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in Adults

NCT00545701 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza
Orthomyxoviridae Infections

Interventions

BIOLOGICAL: A/H5N1 inactivated, split-virion influenza virus

Sponsor

Sanofi Pasteur, a Sanofi Company